Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bloodless end to Boston Biomedica's failed placement:

This article was originally published in Clinica

Executive Summary

Boston Biomedica has managed to exit with some grace and apparently unharmed from its failed stock warrants placement programme with the Paradigm Group and National Securities Corp. Almost two year ago, Boston Biomedica placed an aggregate of 500,000 warrants with the two buyers, but over the course of the registration process, the share price dropped below the option price. The issue last week came to a bloodless close with all parties agreeing to a settlement agreement and mutual release, thereby rescinding or cancelling all obligations to pay exercise prices. Paradigm has also dropped legal proceedings against West Bridgewater, Massachusetts-based Boston Biomedica.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel